The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

ADMA

ADMA Biologics, Inc.

Healthcare · Biotechnology

Overall research band Mixed
Quality Above average
Valuation Weak
Balance sheet Exceptional
Market confirmation Mixed

One-minute company read

What this report can tell you now

What the company does

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes biologic therapies derived from blood plasma. Its main products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments for primary humoral immunodeficiency, and Nabi-HB, which is used for immediate treatment following acute exposure to the Hepatitis B virus. The company is also developing new plasma-derived therapeutics, including immunoglobulin products targeting S. pneumonia infections. ADMA operates its own plasma collection facilities and distributes its products through independent distributors, sales agents, specialty pharmacies, and alternative healthcare providers, serving customers in the United States and internationally.

The current research profile is Mixed Setup, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC38.6%Model input; read with the evidence status and period context.
Operating margin37.5%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years58.4%Model input; read with the evidence status and period context.
FCF margin5.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.